alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 223 studies in Health systems and care delivery · tagged Policy (page 2 of 9) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 223 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

What “Health systems and care delivery” covers

Health systems and care delivery — How health systems organize, coordinate and pay for dementia care, and where and how people with dementia actually receive it.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Medicare Advantage Enrollment and Disenrollment Among Persons With Alzheimer Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 51 out of 100. JAMA Health Forum 2023-09-15

In this cross-sectional study of the Medicare population with acute and postacute care use, beneficiaries with ADRD had increasing enrollment in the Medicare Advantage program, proportional to the growth in overall enrollment, but their disenrollment from Medicare Advantage in the following year remained higher compared with beneficiaries without ADRD. 4 key findings →

Design: cross-sectional Participants: 18 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Trends in Incident Dementia Diagnosis Before and After Medicare Risk Adjustment

✓ Peer-reviewed alzhub usefulness score 50 out of 100. JAMA Network Open 2023-12-15

This cohort study examines rates of new diagnosis of Alzheimer disease and related dementias among beneficiaries of Medicare Advantage plans vs traditional Medicare from 2016 through 2020. 1 key finding →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Primary Care Cost Sharing in Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 50 out of 100. JAMA Health Forum 2026-07-10

Secondary outcomes included plan- and county-level factors associated with offering this benefit in 2025, estimated using multivariable mixed-effects logistic regression with county-level random intercepts. 2 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source

Implications for Policy: The Nursing Home as Least Restrictive Setting

✓ Peer-reviewed alzhub usefulness score 49 out of 100. The Gerontologist 2014-01-17

Measurement using validated tools for resident and family satisfaction and health outcomes showed that culture change interventions or clusters of interventions had few negative impacts, but also seldom resulted in statistically significant improvement. 4 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Epidemiology of Homebound Population Among Beneficiaries of a Large National Medicare Advantage Plan

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Annals of Internal Medicine 2024-08-12

In 2022, the overall prevalence of homebound beneficiaries was 22.0% (8.4% of beneficiaries were homebound, and 13.6% were semihomebound). 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Disparities in Nursing Home Use and Quality Among African American, Hispanic, and White Medicare Residents With Alzheimer’s Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of Aging and Health 2018-05-02

We found that a larger share of Hispanic Medicare residents that are admitted to nursing homes have ADRD compared with African American and White beneficiaries. 3 key findings →

Participants: 1,302,099 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Interdisciplinary Aging Research to Address Health Disparities in Alzheimer’s Disease and Related Dementias: A Scientific Training Program for Early-Career Scholars

✓ Peer-reviewed alzhub usefulness score 49 out of 100. The Journals of Gerontology Series B 2022-10-21

According to the National Institute on Aging (NIA), there are more than 70 associated genes or genetic areas associated with Alzheimer’s when 20 years ago, we knew of only four (Hodes, 2022). 5 key findings →

Design: longitudinal study Participants: 42 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Key lessons to improve care—factors contributing to delayed discharges and cost implications: medical conditions and rehabilitation delays at a tertiary rehabilitation center in Saudi Arabia

✓ Peer-reviewed alzhub usefulness score 48 out of 100. International Journal for Quality in Health Care 2024-04-01

TBI had the highest percentage (37%) compared to other conditions, which may be attributed to the prevalent challenge of cognitive impairment in TBI in addition to physical disability. 5 key findings →

Design: cohort study Participants: 2,285 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer s Disease 2024-11-01

The newly diagnosed ADRD and new AChEI users cohorts included 861,727 and 395,319 patients, respectively. 5 key findings →

Design: cohort study Participants: 861,727 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer s & Dementia 2024-03-13

Prior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Examining annual transitions in healthcare spending among U.S. medicare beneficiaries using multistate Markov models: Analysis of medicare current beneficiary survey data, 2003-2019

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Preventive medicine reports 2023-03-24

Many studies have examined factors associated with individuals of high or low healthcare spending in a given year. 5 key findings →

Design: longitudinal study Participants: 30,729 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Costs, Staffing, and Services of Assisted Living in the United States: A Literature Review

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The health care manager 2016

Assisted-living facilities (ALFs), which provide a community for residents who require assistance throughout their day, are an important part of the long-term-care system in the United States. 5 key findings →

Participants: 32 Evidence: low

Full summary, score breakdown and related studies → Original source

Identifying Medicare beneficiaries with Alzheimer's disease and related dementia using home health OASIS assessments

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Geriatrics Society 2023-06-26

The most important predictors of having a diagnosis of ADRD by the start of care OASIS assessment were a prior discharge diagnosis of ADRD among those admitted from an inpatient setting, and frequently exhibiting symptoms of confusion. 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Medicare's Annual Wellness Visit in a Large Health Care Organization: Who Is Using It?

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Annals of Internal Medicine 2015-10-05

This benefit is being offered at no cost to eligible Medicare recipients; however, recent reports suggest that few persons are taking advantage of it (1–3) and who is using it is unclear. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Risk Adjustment for Alzheimer Disease and Related Dementias in Medicare Advantage and Health Care Experiences

✓ Peer-reviewed alzhub usefulness score 46 out of 100. JAMA Network Open 2026-03-13

Among 5353 MA beneficiary observations (1239 [23.1%] aged 65-74 years; 3127 [58.4%] aged ≥75 years; 1785 male [33.3%]), 1629 (30.4%) reported a diagnosis of ADRD, and 3724 (69.6%) did not report an ADRD diagnosis. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Long‐term outcomes after rehabilitation in Medicare Advantage and fee‐for‐service beneficiaries

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of the American Geriatrics Society 2024-04-10

Among 738 MA and 1488 FFS participants, weighted mean age was 76 years (SD 7.0), 59% were female, and 9% had probable dementia. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Pain Impacting Quality of Life in Persons with Dementia Dying in the Nursing Home by Alternative Medicare Payment Model

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of Palliative Medicine 2022-06-08

There were 115,757 NH residents with dementia who self-reported pain in the last 30 days of life. 5 key findings →

Participants: 20,585 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Medicaid Home and Community-Based Services Initiation and Acute Services Use

✓ Peer-reviewed alzhub usefulness score 46 out of 100. JAMA Health Forum 2026-03-27

In a sample of 1218 new HCBS users (75% female, 77% Black; mean [SD] age, 70.5 [7.5] years), Medicaid HCBS initiation was associated with a decrease in probability of ED use (-2.70 percentage points; 95% CI, -4.18 to -1.22 percentage points) and a decrease in probability of inpatient discharge (-2.63 percentage points; 95% CI, -3.75 to -1.51 percentage points). 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Variability and Potential Determinants of Assisted Living State Regulatory Stringency

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of the American Medical Directors Association 2020-11-29

We examined state variations in assisted living (AL) regulatory policies for admission/retention, staffing/training, medication management, and dementia care. 3 key findings →

Participants: 46 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events